Private Placement

With a former U.S. CTO, WHO expert, and life sciences vet, Welldoc is assembling a powerhouse team to dominate the AI-driven cardiometabolic care market.

Can-Fite BioPharma eyes key 2026 data readouts for its late-stage oral drugs targeting advanced liver cancer, psoriasis, and other unmet medical needs.

As gold, silver, and platinum hit historic highs, Deutsche Bank is issuing new securities for its physically-backed Xtrackers products to meet demand.

Dante's wine expertise meets Early Bird's brunch culture in a new private label Prosecco, a savvy business move tapping into local pride and market trends.

With a $60M backing from a mystery investor, U Power plans to bring its AI-driven battery swapping tech to Southern Europe. Can it succeed?

A breakthrough clinical trial and a savvy financial move could net Fractyl Health $18M to advance its novel obesity treatment beyond the GLP-1 boom.

Biotech Immunome plans a massive stock offering. A deep dive into the high-stakes bet on its cancer pipeline and what it means for investors.

Tiziana's CEO doubles down with a major share purchase, signaling deep faith in a novel MS drug, even as market signals send mixed messages.

NineDot Energy is leveraging battery storage to deliver $60M in energy credits, tackling NYC's affordability crisis and retiring polluting power plants.

A new partnership claims to power an AI with meditated 'love' from at-risk communities. Is this a bold new paradigm or a controversial social experiment?

Weighing less than three sheets of paper, YSMART's Z3RO knife combines tungsten, carbon fiber, and titanium to redefine the everyday carry market.

Udemy bets on AI-powered microlearning to transform skills training. Discover how its new platform caters to busy professionals and redefines online education.

A massive USD 300M investment in a Quebec copper foil plant is set to eliminate a critical EV battery vulnerability for North America. Here's why.

The agtech unicorn is poaching top talent from industry giants. This strategic move signals an aggressive push for global dominance in sustainable agriculture.

An Indiana biotech prepares for biotech's biggest stage, showcasing a pipeline that offers new hope for chronic endocrine and metabolic disorders.

Beyond vaccines, Strand Therapeutics' programmable mRNA shows stunning success in late-stage cancer, heralding a new age of logic-driven genetic medicine.

The crypto giant reports massive growth, but a pivot to AI, operational fires, and rising debt reveal a risky strategy to reshape global computing power.

As New Jersey's cannabis market booms, Grown Rogue's one-year success reveals a potent strategy for blending craft quality with low-cost execution.

Palantir's DGSI contract renewal isn't just a deal; it's a story of strategic reliance, political tension, and the bedrock of its business model.

A C$1M private placement for CHAR Technologies signals strong investor faith in its waste-to-energy tech, promising to decarbonize heavy industry.